Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. 13 de may. de 2024 · Cabotegravir (en español) Generic name: cabotegravir. Brand names: Apretude, Vocabria. Drug class: Integrase strand transfer inhibitor. Medically reviewed by Drugs.com. Last updated on May 13, 2024. Usos. Efectos secundarios. Importante. Dosis. Sobredosis. Que evitar. ¿Qué es cabotegravir?

  2. 15 de may. de 2024 · Suspensión inyectable de liberación prolongada. Medicamento en forma farmaceútica de tipo suspensión inyectable de liberación prolongada, se administra por vía intramuscular, compuesto por 600 mg del principio activo Cabotegravir sodio. Contiene el excipiente Manitol (E-421) (105mg).

  3. 13 de may. de 2024 · Cabotegravir is present in the female and male genital tract. Median cervical and vaginal tissue:plasma ratios ranged from 0.16 to 0.28 and median rectal tissue:plasma ratios were ≤ 0.08 following a single 400 mg intramuscular injection (IM) at 4, 8, and 12 weeks after dosing. Cabotegravir is present in cerebrospinal fluid (CSF).

  4. 9 de may. de 2024 · Cabotegravir y rilpivirine (en español) Generic name: cabotegravir and rilpivirine. Brand names: Cabenuva 400/600, Cabenuva 600/900. Drug class: Antiviral combinations. Medically reviewed by Drugs.com. Last updated on May 19, 2022. Usos. Efectos secundarios.

  5. Hace 4 días · Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration | Open Forum Infectious Diseases | Oxford Academic. Journal Article Accepted manuscript.

  6. 13 de may. de 2024 · Cabotegravir. Generic name: cabotegravir [ KA-boe-TEG-ra-vir ] Brand names: Apretude, Vocabria. Dosage forms: intramuscular suspension, extended release (600 mg/3 mL), oral tablet (30 mg) Drug class: Integrase strand transfer inhibitor. Medically reviewed by Drugs.com on May 13, 2024. Written by Cerner Multum. Uses. Side effects. Warnings.

  7. 7 de may. de 2024 · Cabotegravir is an antiretroviral drug that works by blocking the integrase enzyme, which is required by the HIV-1 virus to replicate in the body. Evidence from clinical trials has shown up to an 88% reduction in HIV-1 among those taking the drug compared to standard PrEP.